Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model
Open Access
- 1 August 1995
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (8) , 1797-1801
- https://doi.org/10.1128/aac.39.8.1797
Abstract
We compared the pharmacodynamics and killing activity of ceftazidime, administered by continuous infusion and intermittent bolus, against Pseudomonas aeruginosa ATCC 27853 and ceftazidime-resistant P. aeruginosa 27853CR with and without a single daily dose of amikacin in an in vitro infection model over a 48-h period. Resistance to ceftazidime was selected for by serial passage of P. aeruginosa onto agar containing increasing concentrations of ceftazidime. Human pharmacokinetics and dosages were simulated as follows: half-life, 2 h; intermittent-bolus ceftazidime, 2 g every 8 h (q8h) and q12h; continuous infusion, 2-g loading dose and maintenance infusions of 5, 10, and 20 micrograms/ml; amikacin, 15 mg/kg q24h. There was no significant difference in time to 99.9% killing between any of the monotherapy regimens or between any combination regimen against ceftazidime-susceptible P. aeruginosa. Continuous infusions of 10 and 20 micrograms/ml killed as effectively as an intermittent bolus of 2 g q12h and q8h, respectively. Continuous infusion of 20 micrograms/ml and an intermittent bolus of 2 g q8h were the only regimens which prevented organism regrowth at 48 h, while a continuous infusion of 5 micrograms/ml resulted in the most regrowth. All of the combination regimens exhibited a synergistic response, with rapid killing of ceftazidime-susceptible P. aeruginosa and no regrowth. Against ceftazidime-resistant P. aeruginosa, none of the ceftazidime monotherapy regimens achieved 99.9% killing. The combination regimens exhibited the same rapid killing of the resistant strain as occurred with the susceptible strain; however, regrowth occurred with all regimens. The combination regimens of continuous infusion of 20 micrograms/ml plus amikacin and intermittent bolus q8h or q12h plus amikacin continued to be synergistic. Overall, continuous infusion monotherapy with ceftazidime at concentrations 4 to 5 and 10 to 15 times the MIC was as effective as an intermittent bolus of 2 g q12h (10 to 15 times the MIC) and q8h (25 to 35 times the MIC), respectively, against ceftazidime-susceptible P. aeruginosa. Combination therapy with amikacin plus ceftazidime, either intermittently q8h or by continuous infusion of 20 micrograms/ml, appeared to be effective and exhibited synergism against ceftazidime-resistant P. aeruginosa.Keywords
This publication has 17 references indexed in Scilit:
- Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Ciprofloxacin Than for CefmenoximeAnnals of Pharmacotherapy, 1994
- Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic modelAntimicrobial Agents and Chemotherapy, 1994
- Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection modelAntimicrobial Agents and Chemotherapy, 1992
- Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection ModelsThe Journal of Infectious Diseases, 1989
- CURE OF PSEUDOMONAS AERUGINOSA INFECTION IN NEUTROPENIC PATIENTS BY CONTINUOUS INFUSION OF CEFTAZIDIMEThe Lancet, 1988
- Artifacts in dilution pharmacokinetic models caused by adherent bacteriaAntimicrobial Agents and Chemotherapy, 1986
- Therapeutic Efficacy of Continuous Versus Intermittent Administration of Ceftazidime in an Experimental Klebsiella pneumoniae Pneumonia in RatsThe Journal of Infectious Diseases, 1985
- Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal modelJournal of Antimicrobial Chemotherapy, 1985
- Treatment of gram-negative bacillary septicemia with cefoperazoneEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983
- A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patientsThe American Journal of Medicine, 1979